Supporting Information
Title: Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and its structure-activity relationships
Authors: Xiantao Wang, Anthony J. Di Pasqua, Sudha Govind, Erin McCracken, Charles Hong, Lixin Mi, Yuehua Mao, Jessie Yu-Chieh Wu, York Tomita, Jordan C. Woodrick, Robert L. Fine, and Fung-Lung Chung (Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University)

**PEITC depletes p53 mutant in H596 cells through an ubiquitination-independent pathway.** (A) Pretreatment of H596 cells with S26 proteasome inhibitor MG132 or Bortezomib (BTZ) has no effect on PEITC-induced mutant p53 depletion. MG132 or BTZ was added 2 h before PEITC. (B) Pretreatment of cells with MDM2 inhibitor Nutlin-3 had no effect on PEITC-induced mutant p53 depletion. Nutlin-3 was added 1 h before PEITC. (C) As a positive control, we showed that MG132 or Nutlin-3 treatment increased wild type p53 protein levels in MCF-7 cells.